Mathias Jachs
@mathiasjachs
Followers
141
Following
338
Media
7
Statuses
86
Clinician Scientist (M.D. Ph.D.) | Medical University of Vienna Hepatic hemodynamics | Viral hepatitis
Joined August 2013
Zwei Forschungsinitiativen der #MedUniWien wurden mit dem „Creating Possible Award“ durch @GileadSciences Österreich ausgezeichnet ⤵️ 🌟 Wir gratulieren @mathiasjachs und @ThomasSzekeres von der MedUni Wien zur Auszeichnung für ihre Forschungsprojekte! ⬇️
meduniwien.ac.at
5
3
13
🆕 Identification of optimal portal pressure decrease to control #ascites while minimizing HE after #TIPS: A multicenter study 💡60-80% PPG reduction = reduced ascites w/o increased oHE risk! 👥 M. Kabelitz et al in Hepatology 🔗 https://t.co/JPmrHqenNN
#livertwitter #liverx
0
11
25
A screening #study at #MedUniVienna has shown that the #infection with the #HepatitisDVirus often remained undetected. Seamless testing at #UniversityHospitalVienna increases the diagnosis rate. The results have been published in @SciReports! ⬇️
meduniwien.ac.at
0
2
10
Spleen stiffness measurements for prediction of clinically significant portal hypertension in patients with compensated advanced chronic liver disease - new in @LancetGastroHep A summary👉 https://t.co/l7BhJbglpo
#LiverTwitter @BavenoCoop @MattiasMandorf1 @mathiasjachs
linkedin.com
Spleen stiffness measurements for prediction of clinically significant portal hypertension in patients with compensated advanced chronic liver disease - new in The Lancet Gastroenterology & Hepatol...
0
6
22
🚨#livertwitter
#SpleenStiffness Measurement #SSM by dedicated 100Hz #VCTE #Fibroscan probe improves #PortalHypertension risk assessment 🎯 #NICER model by @mathiasjachs @MattiasMandorf1 for the @BavenoCoop published @LancetGastroHep 📕 https://t.co/eZ5GRrhLzC
4
23
62
New research - Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with cACLD https://t.co/q445MTVKRD
#LiverTwitter @BavenoCoop @MattiasMandorf1
thelancet.com
The addition of SSM to LSM, BMI, and platelet count outperformed the ANTICIPATE±NASH model for CSPH risk stratification in our cohort of contemporary patients with cACLD. SSM improves the non-invas...
2
13
32
Digging up more evidence demonstrating NSBB are 👑 in Hepatology: This @Gut_BMJ study shows that NSBB may reduce systemic inflammation & NSBB-related WBC 📉 is associated with decreased decompensation & 🪦 @mathiasjachs @ReibergerThomas #livertwitter
https://t.co/M0GdVZJq7P
gut.bmj.com
Objective Systemic inflammation promotes the development of clinical events in patients with advanced chronic liver disease (ACLD). We assessed whether (1) non-selective beta blocker (NSBB) treatment...
0
6
13
Day2️⃣ #Deutsche_Leberstiftung 20. HepNet #MHH @HeinerWedemeyer #MichaelManns @CornbergMarkus 🎬 kicking off updates from #EASL @EASLedu @EASLnews @EASLEUAffairs 👉🏻🦠 Hepatitis @mathiasjachs 👀 the way to #cure 👉🏻#metabolism Prof. Demir @ChariteBerlin curing #firbosis #SLD
0
3
18
@mathiasjachs & the Non-Invasive CSPH Estimated Risk (NICER) model based on a contemporary cohort integrating SSM-100Hz 👏 👉 Developed in SLD & 🦠 suppression/cure 👉 Improved discrimination & calibration. 👉 It's just the NICER model, I guess! 😜 Thanks @BavenoCoop!
1
7
23
Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient #OpenAccess here👉 https://t.co/XRFh7D2ej0
@mathiasjachs
@MattiasMandorf1
#LiverTwitter
1
29
86
#LiverTwitter 3 Relay Teams of the @ViennaLiverNews have finished 🥇🥈🥉 Vienna City Marathon #VCM2024 🏃🏻🏃🏻♂️ for #Liver #Disease Awareness
0
3
25
#twitterliver 👋#PortalHypertension Fans !! Meet the apsiring members 👩🔬🧑🔬👨⚕️👩⚕️ of the clinical research group MOTION divided in 8 work packages assigned to their unique expertise...… ⬇️Follow for more insights…⬇️
0
5
14
🆕Article in press❕ Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta 🔓#OpenAccess at👉 https://t.co/PezSlEtDsj
#LiverTwitter
0
2
20
🆕Validation of #Baveno VII criteria & NIT for CSPH in #hepatitis delta ✅NIT identify high-risk HDV-cACLD patients similar to HVPG w/high accuracy 💡NIT may guide novel antiviral treatment prioritization & individualized prognostication 🔗 https://t.co/C9gib9Miki
#livertwitter
1
2
9
Now publicly available (open access)! @JHepatology @EASLedu
0
0
2
Thanks to everyone at @Maasoumy_lab for being such wonderful hosts! I really enjoy(ed) my time here in Hannover and the cooperation.
0
0
4
Everything seems different in HDV! 🙀 … is it, though? ✅ CSPH drives decompensation ✅ NIT accurately identify at-risk patients 💡NIT facilitate prognostication in HDV-cACLD & may guide prioritization for novel antivirals (update NIT yearly!) 🔗 https://t.co/v1l0PycKWM
3
3
15
🌶️ Elastography needed for diagnosing cACLD & CSPH? 🌶️ 👉 Forget the surrogate fibrosis, think of 👪 & their risk 👉 FIB-4 >= 1.75 ~ LSM >= 10kPa by VCTE. Age is no concern! 👉 VITRO >= 2.5 👉 CSPH ruled-in. 👉 🩸-based non-proprietary NIT - same info as LSM! #LiverTwitter 🔗👇
2
20
57
#LiverTwitter Prognostic performance of non-invasive tests #NITs for portal hypertension #CSPH yield similar prognostic information as measurement of hepatic venous pressure gradient #HVPG
https://t.co/LpnzcGJTpm
0
14
40